Wrazliwosc na cefazoline i ceftazydym metycylinowrazliwych i metycylinoopornych szczepow z rodzaju Staphylococcus

• Autorzy: Wiktorowicz-Belzyt E. , Wojak I. , Janicka G.
• Języki publikacji: PL

Abstrakty

EN

365 S. aureus and 165 Coagulase Negative Staphylococci were tested fur susceptibility to methicillin, cefazolin, cefamandole and ceftazidime by standard broth microdilution and disc method. In staphylococci resistance to methicillin normally parallels resistance to ß-lactams, and it has been suggested that cephalosporins are not he used clinically if susceptbility tests show resistance to methicillin. Populations of methicillin resistant staphylococci are made up of a mixture of methicillin-susceptible and methicillin-resisistant cells (heteroresistant isolates). This phenomenon is the cause of differences in resistance in vitro to methicillin and tested cephalosporins. Cefamandole was the cephalosporin which retained most antibacterial activity against some methicillin-resistant isolates (MlCm MRSA = 63,2 mg/L, MICm MRSA = 67.4 mg/L). This antibiotic has extremely small resistant subpopulations, only detectable by hisih -in- oculum screening or prolonged incubation of isolates in the presence of the drug. Cefazolin was the cephalosporin which had most antibacterial activity against all methicillin-susceptible isolates (MlCm MSSA = 1,3 mg/L, MICm MSCNS = 1,6 mg/L. Among the 3 studied cephalosporins ceftazidime was found to be the least active against methicillin-resistant and methicillin-susceptible Staphylococci (MICm MSSA = 25 mg/L, MICm MRSA = 334,5 mg/L, MICm MRCNS = 414,6 mg/L, MICm MSCNS = 26,7 mg/L)

Słowa kluczowe

PL

szczepy metycylinowrazliwe; Staphylococcus; szczepy bakteryjne; wrazliwosc na cefazoline; szczepy metycylinooporne; wrazliwosc na cefamandol; opornosc na metycyline; wrazliwosc na ceftazydym

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 1997
• Tom: 49
• Numer: 1-2
• Opis fizyczny: s.35-43,tab.,bibliogr.

Twórcy

autor

Wiktorowicz-Belzyt E.

• Akademia Medyczna, 85-094 Bydgoszcz, ul.M.Sklodowskiej-Curie 9

autor

Wojak I.

autor

Janicka G.

Bibliografia

• 1. Archer L.G., Climo H.W.: Antimicrob. Agents Chemother., 1994, 10, 2231.
• 2. Berry H.I., Johnston J.L.: Antimicrob. Agents Chemother.,1986, 29, 748.
• 3. Davies A.J.: Br. Med. J., 1985, 290, 1230.
• 4. Di Píro J.T., Bowden T.A.: Jama, 1984, 6, 98.
• 5. Drumm J., Donovan J.H.: J. Hosp. Infect., 1985, 6, 227.
• 6. Frongillo R.F., Bianchi P.: Antimicrob. Agents Chemother., 1984, 5,666.
• 7. Graninger W. : Intersivmedicin in Dialog, 1991, 4, 10.
• 8. Guggenbichler T.: Biennal Conference on Chemotherapy of Infections Diseases, 1991, 15.
• 9. Karchmer A. W., Archer G.L: Ann. Intern. Med., 1983, 98, 447.
• 10. Klimek J.J., Mersik F.J.:. Am. J. Med., 1988, 61, 340.
• 11. Lambert H.P., O Grady F.W.: Antybiotyki i Chemoterapia, Wydawnictwo Medyczne, Warszawa, 1994, 122.
• 12. Laverdiere M., Peterson P.K.: J. Infect. Dis., 1978, 137, 245.
• 13. Laverdiere M., Walter D.: Antimicrob. Agents Chemother., 1978, 4, 669.
• 14. Menzies R.E., Cornere B.M.: Antimicrob. Agents Chemother., 1987, 1, 42.
• 15. NCCLS, Document M2-A4. Villanova, Pa: NCCLS, 1990.
• 16. Price S.B., Flournoy D.J.: Antimicrob. Agents Chemother., 1984 , 9, 962.
• 17. Richards D.M., Brogen R.N.: Drags, 1985, 29, 105.
• 18. Sabath L.D., Barret F.F.: Antimicrob. Agents Chemother., 1968, 6, 302.
• 19. Sabath L.D., Garner C.: Antimicrob. Agents Chemother., 1984, 9, 970.
• 20. Sheagren J.N.: N. Engl. J. Med., 1984, 310, 1437.
• 21. Thornsberry C., Mc Dougal L.K.: J. Clin. Microb., 1988, 18, 1084.